NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reports that the Company has been invited to present on January 12th at the Biotech Showcase™, a conference designed to showcase promising companies and technologies for partnering and investment purposes.
“We have received significant interest from many parties”
Dr. Anil Diwan, President of NanoViricides will outline the Company’s technology and the current drug programs.
“We have received significant interest from many parties,” said Eugene Seymour, MD, the CEO of the Company, adding, “and we have already set up several meetings during this Conference with both pharmaceutical companies and investment bankers. However, there can be no assurance that we will reach an agreement with any of the parties or that if we do reach an agreement, it will be on terms favorable to the Company.”
The Company now has four commercially important drugs in its pipeline, targeting a total market size of approximately $40 Billion. These drugs target HIV, all Influenzas, viral diseases of the external Eye, and Herpes Simplex viral infections including cold sores and genital herpes (HSV). In addition, the Company has R&D programs in collaborations with reputed institutions against several Neglected Tropical Diseases and agents of interest for Biosecurity. These include hemorrhagic fever viruses such as Ebola/Marburg, Dengue, and Rabies, among others.
Our current drug programs include a pan-influenza drug candidate, “FluCide™”. This drug was recently reported to be highly effective against H1N1 influenza in an extremely lethal challenge animal model. All animals treated with FluCide(™) were still surviving when all animals treated with oseltamivir (Tamiflu®) were dead in 8 days. FluCide treated animals continued to survive for a whole extra week beyond those receiving extended oseltamivir treatment (14 days). This long survival time in this extremely lethal challenge model would suggest indefinite survival in other standardized animal models, according to experts. No other anti-influenza drugs in development have been tested with such severe lethal challenge. FluCide is designed to be effective against all influenza A strains and mutants. We anticipate FluCide to be effective against highly pathogenic avian influenzas such as H7 and H9, the epidemic bird flu virus H5N1 (various clades), the current novel H1N1/2009 virus, seasonal influenza viruses, and their mutations.